Viking Therapeutics(us:VKTX)
23.91
-0.99%
Updated on 2025-04-02
Open:24.15
Close:23.91
High:24.54
Low:23.29
Prev Close:24.15
Volume:3.67M
Turnover:87.77M
Turnover Ratio:3.27%
Shares:112.25M
MarketCap:2.68B
| Date | Total | Total Shares | Total Ratio | New | Increased | Decreased |
|---|---|---|---|---|---|---|
| 2024-06-30 | 11 | 77824 | 0.07% | 3 | 4 | 2 |
| 2024-03-31 | 385 | 79804109 | 72.40% | 194 | 76 | 108 |
| 2023-12-31 | 223 | 76333819 | 76.25% | 46 | 61 | 83 |
| 2023-09-30 | 218 | 77481104 | 77.46% | 30 | 62 | 92 |
| 2023-06-30 | 228 | 74449129 | 74.43% | 46 | 66 | 91 |
| 2023-03-31 | 198 | 66129730 | 83.37% | 71 | 48 | 64 |
| 2022-12-31 | 146 | 34308255 | 43.84% | 40 | 34 | 52 |
| 2022-09-30 | 129 | 26615289 | 34.71% | 17 | 23 | 61 |
| date | orgName | total | ratio | changeShares | changeRatio |
|---|---|---|---|---|---|
| 2024-06-30 | Fmr Llc | 16540281 | 14.93% | 192989 | 1.18% |
| 2024-06-30 | Vanguard Group Inc | 10097337 | 9.11% | 2311613 | 29.69% |
| 2024-06-30 | Blackrock Inc. | 6026131 | 5.44% | -2248043 | -27.17% |
| 2024-06-30 | State Street Corp | 5122428 | 4.62% | 1795861 | 53.98% |
| 2024-06-30 | Jpmorgan Chase & Co | 2251671 | 2.03% | 1211513 | 116.47% |
| 2024-06-30 | Geode Capital Management, Llc | 1859082 | 1.68% | -467697 | -20.10% |
| 2024-06-30 | Susquehanna International Group, Llp | 1404715 | 1.27% | 1118798 | 391.30% |
| 2024-06-30 | Pictet Asset Management Holding Sa | 1381374 | 1.25% | 3338 | 0.24% |
| 2024-06-30 | Viking Global Investors Lp | 1354450 | 1.22% | 259510 | 23.70% |
| 2024-06-30 | Alliancebernstein L.P. | 1241125 | 1.12% | -319753 | -20.48% |
About
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.
Address:9920 Pacific Heights Boulevard,Suite 350
Market Movers